×
About 11,100 results

ALLMedicine™ Triple-negative Breast Cancer Center

Research & Reviews  3,425 results

Tumor-infiltrating lymphocytes in early breast cancer: an exploratory analysis focused ...
https://doi.org/10.1080/03007995.2022.2096334
Current Medical Research and Opinion; Luz P, Fernandes I et. al.

Jul 1st, 2022 - Tumor-infiltrating lymphocytes (TILs) have shown prognostic value in breast cancer. This study evaluated the TILs scores in 186 Portuguese patients diagnosed with early breast cancer, with special focus on HER2 subtype. Stromal TILs were scored on...

Highlights in Early Breast Cancer From the 2022 American Society of Clinical Oncology Annual Meeting
https://www.mdedge.com/hematology-oncology/article/255784/highlights-early-breast-cancer-2022-american-society-clinical
Ann H. Partridge, MD, MPH

Jun 29th, 2022 - Dr Ann Partridge from the Dana-Farber Cancer Institute in Boston, Massachusetts, highlights important new data in early breast cancer presented at American Society of Clinical Oncology (ASCO) 2022. Dr Partridge begins with promising results from t.

Triple-negative breast cancer drug resistance, durable efficacy, and cure: How advanced...
https://doi.org/10.1080/14728222.2022.2094762
Expert Opinion on Therapeutic Targets; De Francesco EM, Cirillo F et. al.

Jun 29th, 2022 - Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by the lack of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) and often associated with poor survival outcomes. The bac...

Survival outcome assessment for triple-negative breast cancer: a nomogram analysis base...
https://doi.org/10.1007/s00330-022-08910-4
European Radiology; Sheng DL, Shen XG et. al.

Jun 28th, 2022 - This study aimed to incorporate clinicopathological, sonographic, and mammographic characteristics to construct and validate a nomogram model for predicting disease-free survival (DFS) in patients with triple-negative breast cancer (TNBC). Patient...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  249 results

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03371017

Jun 24th, 2022 - This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Pa...
https://clinicaltrials.gov/ct2/show/NCT04300556

Jun 24th, 2022 - The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin in participants with selected tumor types (ovarian cance...

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04826341

Jun 24th, 2022 - Background: Several small molecule poly-(ADP)-ribose polymerase inhibitors (PARPi) have been approved by the FDA for multiple cancers with homologous recombination (HR) deficiencies. Despite their measurable initial benefit, PARPi resistance is a ...

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
https://clinicaltrials.gov/ct2/show/NCT02595905

Jun 22nd, 2022 - PRIMARY OBJECTIVES: I. To compare the efficacy of cisplatin with or without ABT-888 (veliparib) on progression-free survival (PFS) in each of the following groups: Ia. Patients with germline BRCA (gBRCA) mutation-associated breast cancer. Ib. Pati...

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
https://clinicaltrials.gov/ct2/show/NCT05006794

Jun 22nd, 2022 - The primary objective of Part A of this study is to define the maximum tolerated dose (MTD) or maximum administered dose of GS-9716 as monotherapy in advanced solid malignancies and to characterize the safety, and tolerability of GS-9716 monothera...

see more →

News  763 results

Highlights in Early Breast Cancer From the 2022 American Society of Clinical Oncology Annual Meeting
https://www.mdedge.com/hematology-oncology/article/255784/highlights-early-breast-cancer-2022-american-society-clinical
Ann H. Partridge, MD, MPH

Jun 29th, 2022 - Dr Ann Partridge from the Dana-Farber Cancer Institute in Boston, Massachusetts, highlights important new data in early breast cancer presented at American Society of Clinical Oncology (ASCO) 2022. Dr Partridge begins with promising results from t.

Advanced TNBC: Camrelizumab + apatinib and eribulin shows promise in heavily pretreated patients
https://www.mdedge.com/hematology-oncology/article/255686/breast-cancer/advanced-tnbc-camrelizumab-apatinib-and-eribulin

Jun 23rd, 2022 - Key clinical point: The combination of camrelizumab, apatinib, and eribulin demonstrated a favorable efficacy and a manageable safety profile in patients with heavily pretreated advanced triple negative breast cancer (TNBC). Major finding: The obj.

Breast Cancer Less Common in Black Women, So Why Do More Die?
https://www.medscape.com/viewarticle/975891

Jun 20th, 2022 - Although breast cancer occurs less frequently in Black women compared to White women, they have a much higher risk of dying from the disease. In the United States, age-adjusted breast cancer mortality between 2014 and 2018 was approximately 40% hi...

Sacituzumab a 'Step Forward' in Breast Cancer Unmet Need
https://www.medscape.com/viewarticle/975069

Jun 6th, 2022 - An antibody drug conjugate that targets a cell-surface antigen found on most breast and bladder cancers demonstrated improved progression-free survival over standard chemotherapy in patients with endocrine-resistant hormone receptor positive/HER2 ...

Pembrolizumab before surgery improves survival in early triple negative breast cancer
https://www.mdedge.com/hematology-oncology/article/255208/asco-breast-cancer/pembrolizumab-surgery-improves-survival-early
Walter Alexander

Jun 5th, 2022 - Results of the KEYNOTE-522 clinical trial highlight the importance of neoadjuvant treatment with pembrolizumab for improving survival in patients with early triple negative breast cancer (TNBC). The findings were presented in Chicago June 4 and 5.

see more →

Patient Education  1 results see all →